The SmartTouch for Symbicort is a monitoring device that is installed onto the patient's inhaler to track and improve medication adherence. The Food and Drug Administration (FDA) has granted Adherium ...
Verywell Health on MSN
What to Know About Symbicort (Budesonide and Formoterol)
Medically reviewed by Sanja Jelic, MD Key Takeaways Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler.Before using Symbicort, tell your healthcare ...
The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a ...
DENVER--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced results from a long-term study comparing SYMBICORT ® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with ...
The U.S. Food and Drug Administration said yesterday that it has given approval for the first generic of the Symbicort inhaler to treat asthma and COPD. Symbicort is a combination of budesonide and ...
AstraZeneca Announces Symbicort Is Now Available In The U.S. U.S. Asthma Sufferers Now Have a New Choice of Combination Therapy to Help Achieve Asthma Control LONDON ...
(RTTNews) - The U.S. Food and Drug Administration approved Mylan Pharmaceuticals, Inc.'s generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. It is the first FDA- ...
AstraZeneca PLCAZN announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone. Symbicort is presently marketed for the treatment ...
Wilmington, DE – June 4, 2008 – AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results